| Symbol | SUPN |
|---|---|
| Name | SUPERNUS PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 9715 KEY WEST AVE, ROCKVILLE, Maryland, 20850, United States |
| Telephone | +1 301 - 838-2500 |
| Fax | — |
| — | |
| Website | https://www.supernus.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001356576 |
| Description | Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others. Additional info from NASDAQ: |
2026-08-31 12:30
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
Read more
2026-08-29 11:13
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Read more
2026-08-14 21:11
Rubin Jonathan 🟡 adjusted position in 363 shares (1 derivative) of SUPERNUS PHARMACEUTICALS, INC. (SUPN) at $46.57 Transaction Date: Aug 12, 2026 | Filing ID: 000010
Read more
2026-08-14 21:11
Bhatt Padmanabh P. 🟡 adjusted position in 1.2K shares (1 derivative) of SUPERNUS PHARMACEUTICALS, INC. (SUPN) at $46.57 Transaction Date: Aug 12, 2026 | Filing ID: 000012
Read more
2026-08-14 21:09
DEC TIMOTHY C 🟡 adjusted position in 604 shares (1 derivative) of SUPERNUS PHARMACEUTICALS, INC. (SUPN) at $46.57 Transaction Date: Aug 12, 2026 | Filing ID: 000015
Read more
2026-08-07 15:21
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Read more
2026-08-03 19:13
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
Read more
2026-08-03 18:26
New Form 425 - SUPERNUS PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001193125-26-330875 <b>Size:</b> 217 KB
Read more
2026-08-03 18:06
New Form DEFA14A - SUPERNUS PHARMACEUTICALS, INC. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001104659-26-089849 <b>Size:</b> 2 MB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT02433314 | An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Stat… | — | Super-Refractory Status Epilepticus | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT03924492 | Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patient… | — | Postpartum Depression | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07226661 | Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Phase2 | Major Depressive Disorder (MDD) | Recruiting | 2026-01-19 | 2027-01-31 | ClinicalTrials.gov |
| NCT07125222 | Use of Gocovri to Improve Disability Due to Radiation Encephalopathy | Phase2 | Radiation Encephalopathy | Not_Yet_Recruiting | 2025-09-01 | 2028-08-01 | ClinicalTrials.gov |
| NCT07141329 | SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures | Phase2 | Focal Onset Seizures | Recruiting | 2025-07-30 | 2027-12-31 | ClinicalTrials.gov |
| NCT07219927 | Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusi… | — | Parkinson Disease | Recruiting | 2025-03-31 | 2027-08-01 | ClinicalTrials.gov |
| NCT06798896 | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adult… | Phase2 | Focal Onset Seizures | Recruiting | 2024-12-30 | 2027-08-01 | ClinicalTrials.gov |
| NCT06185985 | Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Completed | 2024-03-25 | 2024-12-11 | ClinicalTrials.gov |
| NCT04781140 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Ch… | Phase4 | Attention-Deficit/Hyperactivity Disorder | Recruiting | 2024-03-19 | 2026-06-01 | ClinicalTrials.gov |
| NCT06235905 | Open-Label of SPN-820 in Adults With Major Depressive Disorder | Phase2 | Major Depressive Disorder | Completed | 2024-02-15 | 2024-08-18 | ClinicalTrials.gov |
| NCT06259331 | Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide In… | Phase4 | Healthy Lactating Women | Completed | 2023-05-23 | 2023-09-20 | ClinicalTrials.gov |
| NCT05645432 | An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus | Phase2 | Tinnitus | Completed | 2023-05-10 | 2023-11-21 | ClinicalTrials.gov |
| NCT05518578 | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resis… | Phase2 | Epilepsy | Recruiting | 2023-02-07 | 2027-12-31 | ClinicalTrials.gov |
| NCT05655520 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants Wit… | Phase3 | Huntington's Disease | Terminated | 2022-12-14 | 2025-01-20 | ClinicalTrials.gov |
| NCT05619692 | A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive… | Phase2 | Mild Cognitive Impairment | Completed | 2022-11-29 | 2024-07-09 | ClinicalTrials.gov |
| NCT05318937 | A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Di… | Phase2 | Parkinson Disease | Completed | 2022-06-06 | 2024-02-23 | ClinicalTrials.gov |
| NCT05358821 | 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntingto… | Phase2 | Huntington Disease | Completed | 2022-05-26 | 2024-04-10 | ClinicalTrials.gov |
| NCT05107128 | A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participant… | Phase2 | Huntington's Disease | Completed | 2022-01-26 | 2024-10-03 | ClinicalTrials.gov |
| NCT05066672 | Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression | Phase2 | Treatment Resistant Depression | Completed | 2022-01-18 | 2025-01-21 | ClinicalTrials.gov |
| NCT04815967 | Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spas… | Phase2 | Spasticity | Active_Not_Recruiting | 2021-11-16 | 2024-07-01 | ClinicalTrials.gov |
| NCT05152680 | Mass Balance Study of NV-5138 in Healthy Male Subjects. | Phase1 | Healthy Volunteers | Completed | 2021-11-11 | 2021-12-09 | ClinicalTrials.gov |
| NCT05384977 | Mass Balance Study of NV-5138 in Healthy Male Subjects | Phase1 | Healthy Volunteers | Completed | 2021-11-11 | 2021-12-09 | ClinicalTrials.gov |
| NCT05102552 | Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments … | Early_Phase1 | Healthy Volunteer | Completed | 2021-10-19 | 2022-08-15 | ClinicalTrials.gov |
| NCT05059600 | A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a … | Phase4 | Postpartum Depression | Completed | 2021-10-08 | 2022-07-14 | ClinicalTrials.gov |
| NCT05049343 | Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Saf… | Phase1 | Healthy Volunteer | Completed | 2021-09-21 | 2021-12-03 | ClinicalTrials.gov |
| NCT04786990 | Open-Label Study of SPN-812 Administered With Psychostimulants in Children and … | Phase4 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2021-07-27 | 2023-07-26 | ClinicalTrials.gov |
| NCT04602624 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants Wit… | Phase2 | Alzheimer Disease | Completed | 2020-12-07 | 2021-09-28 | ClinicalTrials.gov |
| NCT04476017 | A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants Wit… | Phase2 | Parkinson Disease | Completed | 2020-07-31 | 2022-03-25 | ClinicalTrials.gov |
| NCT04050293 | Therapy for Migraine Prevention in Children 6-11 Years of Age | Phase4 | Migraine Disorders | Terminated | 2020-07-14 | 2023-03-01 | ClinicalTrials.gov |
| NCT04143217 | Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-releas… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Completed | 2020-01-23 | 2022-12-14 | ClinicalTrials.gov |
| NCT04099667 | Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spas… | Phase2 | Spasticity | Unknown | 2019-12-17 | 2024-07-01 | ClinicalTrials.gov |
| NCT04016779 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD | Phase3 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2019-11-20 | 2020-10-10 | ClinicalTrials.gov |
| NCT04016792 | Classroom Study of SPN-812 in Children With ADHD | Phase3 | ADHD | Withdrawn | 2019-08-01 | 2020-11-01 | ClinicalTrials.gov |
| NCT03638466 | Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children Wi… | Phase2 | Attention Deficit Hyperactivity Disorder (ADHD) | Terminated | 2019-05-30 | 2019-11-07 | ClinicalTrials.gov |
| NCT03787758 | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral… | Phase1 | Huntington Disease | Completed | 2019-02-28 | 2019-10-07 | ClinicalTrials.gov |
| NCT03844906 | A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics… | Phase1 | Healthy Volunteer | Completed | 2018-12-27 | 2019-04-01 | ClinicalTrials.gov |
| NCT03770780 | A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics… | Phase1 | Healthy Volunteer | Completed | 2018-11-12 | 2019-03-22 | ClinicalTrials.gov |
| NCT03771586 | A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokine… | Phase1 | Healthy Volunteer | Completed | 2018-09-24 | 2019-01-02 | ClinicalTrials.gov |
| NCT03665038 | A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Fema… | Phase3 | Post Partum Depression | Completed | 2018-09-07 | 2021-01-08 | ClinicalTrials.gov |
| NCT03615703 | Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors | — | Impulsive Aggression | Completed | 2018-08-10 | 2019-03-15 | ClinicalTrials.gov |
| NCT03597503 | Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction W… | Phase3 | Attention Deficit Hyperactivity Disorder | Terminated | 2018-07-31 | 2020-01-22 | ClinicalTrials.gov |
| NCT03474770 | BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures | Phase1 | Focal Impaired Awareness Seizures | Active_Not_Recruiting | 2018-04-10 | 2026-12-30 | ClinicalTrials.gov |
| NCT03944785 | Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO… | — | Idiopathic Parkinson Disease | Completed | 2017-11-30 | 2020-01-10 | ClinicalTrials.gov |
| NCT03247556 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adoles… | Phase3 | ADHD | Completed | 2017-11-20 | 2019-02-14 | ClinicalTrials.gov |
| NCT03247517 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolesc… | Phase3 | ADHD | Completed | 2017-11-02 | 2018-10-17 | ClinicalTrials.gov |
| NCT03247543 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Childr… | Phase3 | ADHD | Completed | 2017-10-31 | 2018-10-17 | ClinicalTrials.gov |
| NCT03280342 | Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramat… | Phase2 | Migraine | Withdrawn | 2017-10-30 | 2018-09-13 | ClinicalTrials.gov |
| NCT03247530 | Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Childre… | Phase3 | ADHD | Completed | 2017-10-20 | 2018-09-12 | ClinicalTrials.gov |
| NCT03156439 | Bioavailability, Safety, and Tolerability of BIS-001 ER | Phase1 | Epilepsy, Complex Partial | Completed | 2017-05-22 | 2017-09-30 | ClinicalTrials.gov |
| NCT02942004 | A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe… | Phase3 | Postpartum Depression | Completed | 2016-08-01 | 2017-10-19 | ClinicalTrials.gov |
| NCT02942017 | A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Modera… | Phase3 | Postpartum Depression | Completed | 2016-07-01 | 2017-10-11 | ClinicalTrials.gov |
| NCT02691182 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Sta… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Terminated | 2016-04-01 | 2021-05-01 | ClinicalTrials.gov |
| NCT02618434 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Sta… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2016-02-16 | 2020-02-14 | ClinicalTrials.gov |
| NCT02736656 | Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazi… | Phase3 | Attention-Deficit/Hyperactivity Disorder | Active_Not_Recruiting | 2016-02-02 | 2026-09-01 | ClinicalTrials.gov |
| NCT02633527 | Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Childre… | Phase2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2016-02-01 | 2016-07-25 | ClinicalTrials.gov |
| NCT02618408 | Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Sta… | Phase3 | Attention Deficit Hyperactivity Disorder (ADHD) | Completed | 2016-01-25 | 2019-10-24 | ClinicalTrials.gov |
| NCT02549573 | Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease C… | Phase4 | Parkinson's Disease | Terminated | 2016-01-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02614547 | A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression | Phase2 | Severe Postpartum Depression | Completed | 2015-12-15 | 2016-06-22 | ClinicalTrials.gov |
| NCT02477618 | A Study With SAGE-547 for Super-Refractory Status Epilepticus | Phase3 | Super-Refractory Status Epilepticus | Completed | 2015-06-01 | 2017-08-11 | ClinicalTrials.gov |
| NCT02339064 | Infusion of Apomorphine: Long-term Safety Study | Phase3 | Idiopathic Parkinson's Disease | Active_Not_Recruiting | 2015-02-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT02285504 | Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression | Phase2 | Postpartum Depression | Completed | 2015-01-07 | 2015-06-05 | ClinicalTrials.gov |
| NCT02052739 | Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of… | Phase1 | Super-refractory Status Epilepticus | Completed | 2014-03-21 | 2015-05-03 | ClinicalTrials.gov |
| NCT02023606 | Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labe… | Phase1 | Impulsive Aggression Comorbid With ADHD | Completed | 2013-11-01 | 2013-12-01 | ClinicalTrials.gov |
| NCT01770145 | Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) | Phase4 | Parkinson's Disease | Completed | 2012-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01416064 | Open-Label, Extension Study to 810P202 | Phase2 | Impulsive Aggression Comorbid With ADHD in Children | Completed | 2011-09-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01364662 | A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in… | Phase2 | Impulsive Aggression Comorbid With ADHD | Completed | 2011-06-01 | 2012-10-01 | ClinicalTrials.gov |
| NCT01284530 | Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjun… | Phase1 | Epilepsy | Completed | 2011-01-01 | 2012-06-01 | ClinicalTrials.gov |
| NCT01114854 | A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of… | Phase1 | Epilepsy | Completed | 2010-06-01 | 2011-01-01 | ClinicalTrials.gov |
| NCT01107496 | Evaluation of Immediate-Release Viloxazine in Adults With ADHD | Phase1 | Attention-Deficit/Hyperactivity Disorder (ADHD) | Completed | 2010-06-01 | 2010-12-01 | ClinicalTrials.gov |
| NCT00918424 | Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects | — | Epilepsy | Approved_For_Marketing | 2009-06-01 | — | ClinicalTrials.gov |
| NCT00918047 | Study of PK and Safety of OXC (Oxcarbazepine) XR (Extended Release) as Adjuncti… | Phase1 | Epilepsies, Partial | Completed | 2009-06-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT00908349 | Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refrac… | Phase3 | Partial Epilepsy | Completed | 2009-06-01 | 2011-11-01 | ClinicalTrials.gov |
| NCT00772603 | Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial S… | Phase3 | Epilepsies, Partial | Completed | 2008-11-01 | 2010-11-01 | ClinicalTrials.gov |
| NCT01246765 | National Pregnancy Registry for Psychiatric Medications | — | Pregnant Women | Recruiting | 2008-11-01 | 2033-12-01 | ClinicalTrials.gov |
| NCT00626236 | Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and … | Phase2 | Attention Deficit Disorder With Hyperactivity | Completed | 2008-10-21 | 2009-09-23 | ClinicalTrials.gov |
Total clinical trials: 75
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| SPN-812 | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | ACTIVE_NOT_RECRUITING | NCT02736656 |
| Placebo | Other | Phase PHASE2 | Focal Onset Seizures | RECRUITING | NCT06798896 |
| SPN-817 | Other | Phase PHASE2 | Focal Onset Seizures | RECRUITING | NCT06798896 |
| SAGE-718 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT04476017 |
| SPN-810M | Other | Phase PHASE1 | Impulsive Aggression Comorbid With ADHD | COMPLETED | NCT02023606 |
| TPM XR | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01284530 |
| Molindone | Other | Phase PHASE2 | Impulsive Aggression Comorbid With ADHD in Children | COMPLETED | NCT01416064 |
| Topiramate ER | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01114854 |
| Topiramate IR | Other | Phase PHASE1 | Epilepsy | COMPLETED | NCT01114854 |
| BIS-001 ER | Other | Phase PHASE1 | Epilepsy, Complex Partial | COMPLETED | NCT03156439 |
| 200 mg SPN-812 | Other | Phase PHASE3 | ADHD | WITHDRAWN | NCT04016792 |
| Placebo | Other | Phase PHASE3 | ADHD | WITHDRAWN | NCT04016792 |
| XR-TPM (Trokendi XR) | Other | Phase PHASE2 | Migraine | WITHDRAWN | NCT03280342 |
| IR-TPM (Topamax) | Other | Phase PHASE2 | Migraine | WITHDRAWN | NCT03280342 |
| Placebo | Other | Phase PHASE2 | Impulsive Aggression Comorbid With ADHD | COMPLETED | NCT01364662 |
| SPN-810 | Other | Phase PHASE2 | Impulsive Aggression Comorbid With ADHD | COMPLETED | NCT01364662 |
| 400mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247517 |
| 200mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247517 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247517 |
| 600mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247556 |
| 400mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247556 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247556 |
| 200mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247530 |
| 100mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247530 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247530 |
| 400mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247543 |
| 200mg SPN-812 | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247543 |
| Placebo | Other | Phase PHASE3 | ADHD | COMPLETED | NCT03247543 |
| 400mg SPN-812 | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT02633527 |
| 300mg SPN-812 | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT02633527 |
| 200mg SPN-812 | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT02633527 |
| 100mg SPN-812 | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT02633527 |
| Placebo | Other | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT02633527 |
| [14C]-NV-5138 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05152680 |
| [14C]-NV-5138 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05384977 |
| SPN-812 | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT04016779 |
| Placebo | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT04016779 |
| BIS-001, Treatment A | Drug | Phase EARLY_PHASE1 | Healthy Volunteer | COMPLETED | NCT05102552 |
| SPN-817, Treatment C | Drug | Phase EARLY_PHASE1 | Healthy Volunteer | COMPLETED | NCT05102552 |
| SPN-817, Treatment B | Drug | Phase EARLY_PHASE1 | Healthy Volunteer | COMPLETED | NCT05102552 |
| BIS-001ER | Other | Phase PHASE1 | Focal Impaired Awareness Seizures | ACTIVE_NOT_RECRUITING | NCT03474770 |
| Phase 3; Placebo | Other | Phase PHASE2 | Spasticity | ACTIVE_NOT_RECRUITING | NCT04815967 |
| Phase 3; MYOBLOC | Other | Phase PHASE2 | Spasticity | ACTIVE_NOT_RECRUITING | NCT04815967 |
| Phase 2; Placebo | Other | Phase PHASE2 | Spasticity | ACTIVE_NOT_RECRUITING | NCT04815967 |
| Phase 2; High Dose MYOBLOC | Other | Phase PHASE2 | Spasticity | ACTIVE_NOT_RECRUITING | NCT04815967 |
| Phase 2; Low Dose MYOBLOC | Other | Phase PHASE2 | Spasticity | ACTIVE_NOT_RECRUITING | NCT04815967 |
| Phase 3; Placebo | Other | Phase PHASE2 | Spasticity | UNKNOWN | NCT04099667 |
| Phase 3; MYOBLOC | Other | Phase PHASE2 | Spasticity | UNKNOWN | NCT04099667 |
| Phase 2; Placebo | Other | Phase PHASE2 | Spasticity | UNKNOWN | NCT04099667 |
| Phase 2; High Dose MYOBLOC | Other | Phase PHASE2 | Spasticity | UNKNOWN | NCT04099667 |
| Phase 2; Low Dose MYOBLOC | Other | Phase PHASE2 | Spasticity | UNKNOWN | NCT04099667 |
| XADAGO (safinamide) | Other | Preclinical | Idiopathic Parkinson Disease | COMPLETED | NCT03944785 |
| Trimethobenzamide | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| L-dopa | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| APOKYN | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| Trimethobenzamide | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| L-dopa | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| APOKYN | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| Trimethobenzamide | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| L-dopa | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| APOKYN | Other | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| Physical Therapy | Drug | Phase PHASE4 | Parkinson's Disease | TERMINATED | NCT02549573 |
| APOKYN | Other | Phase PHASE4 | Parkinson's Disease | TERMINATED | NCT02549573 |
| Physical Therapy | Drug | Phase PHASE4 | Parkinson's Disease | TERMINATED | NCT02549573 |
| APOKYN | Other | Phase PHASE4 | Parkinson's Disease | TERMINATED | NCT02549573 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618408 |
| SPN-810 (36 mg) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618408 |
| SPN-810 (18 mg) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618408 |
| SPN-812 | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT04143217 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618434 |
| SPN-810 (36 mg) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618434 |
| SPN-810 (18 mg) | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618434 |
| Placebo | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT03597503 |
| SPN-810 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder | TERMINATED | NCT03597503 |
| SPN-812 | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT04786990 |
| SPN-810 | Other | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT02691182 |
| SPN-812 (600mg, QD) | Other | Phase PHASE4 | Healthy Lactating Women | COMPLETED | NCT06259331 |
| Placebo | Other | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT01107496 |
| IR Viloxazine | Other | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT01107496 |
| Placebo | Other | Phase PHASE2 | Focal Onset Seizures | RECRUITING | NCT06798896 |
| SPN-817 | Other | Phase PHASE2 | Focal Onset Seizures | RECRUITING | NCT06798896 |
| Placebo | Other | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
| SPN-810 | Other | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
| Point Subtraction Aggression Paradigm (PSAP) Task | Other | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
| Magnetic Resonance Spectroscopy (MRS) | Other | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
| Functional Magnetic Resonance Imaging (fMRI) | Other | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
| apomorphine infusion | Other | Phase PHASE3 | Idiopathic Parkinson's Disease | ACTIVE_NOT_RECRUITING | NCT02339064 |
| SPN-812 | Other | Phase PHASE3 | Attention-Deficit/Hyperactivity Disorder | ACTIVE_NOT_RECRUITING | NCT02736656 |
| Gocovri (extended-release amantidine) | Other | Phase PHASE2 | Radiation Encephalopathy | NOT_YET_RECRUITING | NCT07125222 |
| SAGE-718 | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05318937 |
| SAGE-718-matching placebo | Other | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05318937 |
| Brexanolone | Other | Phase PHASE2 | Tinnitus | COMPLETED | NCT05645432 |
| SAGE-718-matching Placebo | Other | Phase PHASE2 | Mild Cognitive Impairment | COMPLETED | NCT05619692 |
| SAGE-718 | Other | Phase PHASE2 | Mild Cognitive Impairment | COMPLETED | NCT05619692 |
| Placebo | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT05358821 |
| SAGE-718 | Other | Phase PHASE2 | Huntington Disease | COMPLETED | NCT05358821 |
| Placebo | Other | Phase PHASE2 | Huntington's Disease | COMPLETED | NCT05107128 |
| SAGE-718 | Other | Phase PHASE2 | Huntington's Disease | COMPLETED | NCT05107128 |
| ZULRESSO® | Other | Phase PHASE4 | Postpartum Depression | COMPLETED | NCT05059600 |
| SAGE-718 | Other | Phase PHASE2 | Alzheimer Disease | COMPLETED | NCT04602624 |
| ZULRESSO (brexanolone) injection | Other | Preclinical | Postpartum Depression | APPROVED_FOR_MARKETING | NCT03924492 |
| Brexanolone | Other | Phase PHASE3 | Post Partum Depression | COMPLETED | NCT03665038 |
| SAGE-547 90 μg/kg/h | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942017 |
| Placebo | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942017 |
| Placebo | Other | Phase PHASE2 | Severe Postpartum Depression | COMPLETED | NCT02614547 |
| SAGE-547 | Other | Phase PHASE2 | Severe Postpartum Depression | COMPLETED | NCT02614547 |
| SAGE-547 | Other | Preclinical | Super-Refractory Status Epilepticus | NO_LONGER_AVAILABLE | NCT02433314 |
| SAGE-547 | Other | Phase PHASE2 | Postpartum Depression | COMPLETED | NCT02285504 |
| SAGE-547 | Other | Phase PHASE1 | Super-refractory Status Epilepticus | COMPLETED | NCT02052739 |
| Ketamine | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05049343 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05049343 |
| SAGE-904 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05049343 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03844906 |
| SAGE-718 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03844906 |
| SAGE-718 | Other | Phase PHASE1 | Huntington Disease | COMPLETED | NCT03787758 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03771586 |
| SAGE-718 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03771586 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03770780 |
| SAGE-718 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT03770780 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder (MDD) | RECRUITING | NCT07226661 |
| SPN-821 2400 mg | Other | Phase PHASE2 | Major Depressive Disorder (MDD) | RECRUITING | NCT07226661 |
| SPN-817 | Other | Phase PHASE2 | Focal Onset Seizures | RECRUITING | NCT07141329 |
| SAGE-547 90 μg/kg/h | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942004 |
| SAGE-547 60 μg/kg/h | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942004 |
| Placebo | Other | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942004 |
| Placebo | Other | Phase PHASE3 | Super-Refractory Status Epilepticus | COMPLETED | NCT02477618 |
| SAGE-547 | Other | Phase PHASE3 | Super-Refractory Status Epilepticus | COMPLETED | NCT02477618 |
| NV-5138 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT06235905 |
| Observational study | Other | Preclinical | Parkinson Disease | RECRUITING | NCT07219927 |
| SAGE-718 | Other | Phase PHASE3 | Huntington's Disease | TERMINATED | NCT05655520 |
| Placebo | Other | Phase PHASE4 | Migraine Disorders | TERMINATED | NCT04050293 |
| SPN-538 | Other | Phase PHASE4 | Migraine Disorders | TERMINATED | NCT04050293 |
| Placebo | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | RECRUITING | NCT04781140 |
| 100mg SPN-812 | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | RECRUITING | NCT04781140 |
| SPN-812 | Other | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT06185985 |
| matched placebo | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05066672 |
| NV-5138 | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05066672 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| SPN-817 | Other | Phase PHASE2 | Epilepsy | RECRUITING | NCT05518578 |
| matched placebo | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05066672 |
| NV-5138 | Other | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05066672 |
| SPN-821 2400 mg | DRUG | Phase PHASE2 | Major Depressive Disorder (MDD) | RECRUITING | NCT07226661 |
| Observational study | OTHER | Preclinical | Parkinson Disease | RECRUITING | NCT07219927 |
| Gocovri (extended-release amantidine) | DRUG | Phase PHASE2 | Radiation Encephalopathy | NOT_YET_RECRUITING | NCT07125222 |
| SPN-812 (600mg, QD) | DRUG | Phase PHASE4 | Healthy Lactating Women | COMPLETED | NCT06259331 |
| SAGE-718-matching Placebo | DRUG | Phase PHASE2 | Mild Cognitive Impairment | COMPLETED | NCT05619692 |
| SPN-817 | DRUG | Phase PHASE2 | Focal Onset Seizures | RECRUITING | NCT07141329 |
| SAGE-718-matching placebo | DRUG | Phase PHASE2 | Parkinson Disease | COMPLETED | NCT05318937 |
| [14C]-NV-5138 | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT05384977 |
| BIS-001, Treatment A | DRUG | Phase EARLY_PHASE1 | Healthy Volunteer | COMPLETED | NCT05102552 |
| SPN-817, Treatment C | DRUG | Phase EARLY_PHASE1 | Healthy Volunteer | COMPLETED | NCT05102552 |
| SPN-817, Treatment B | DRUG | Phase EARLY_PHASE1 | Healthy Volunteer | COMPLETED | NCT05102552 |
| matched placebo | DRUG | Phase PHASE2 | Treatment Resistant Depression | COMPLETED | NCT05066672 |
| NV-5138 | DRUG | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT06235905 |
| ZULRESSO® | DRUG | Phase PHASE4 | Postpartum Depression | COMPLETED | NCT05059600 |
| Ketamine | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05049343 |
| SAGE-904 | DRUG | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT05049343 |
| Phase 3; Placebo | DRUG | Phase PHASE2 | Spasticity | UNKNOWN | NCT04815967 |
| Phase 3; MYOBLOC | DRUG | Phase PHASE2 | Spasticity | UNKNOWN | NCT04815967 |
| Phase 2; Placebo | DRUG | Phase PHASE2 | Spasticity | UNKNOWN | NCT04815967 |
| Phase 2; High Dose MYOBLOC | DRUG | Phase PHASE2 | Spasticity | UNKNOWN | NCT04815967 |
| Phase 2; Low Dose MYOBLOC | DRUG | Phase PHASE2 | Spasticity | UNKNOWN | NCT04815967 |
| SPN-538 | DRUG | Phase PHASE4 | Migraine Disorders | TERMINATED | NCT04050293 |
| 200 mg SPN-812 | DRUG | Phase PHASE3 | ADHD | WITHDRAWN | NCT04016792 |
| XADAGO (safinamide) | DRUG | Preclinical | Idiopathic Parkinson Disease | COMPLETED | NCT03944785 |
| ZULRESSO (brexanolone) injection | DRUG | Preclinical | Postpartum Depression | APPROVED_FOR_MARKETING | NCT03924492 |
| SAGE-718 | DRUG | Phase PHASE3 | Huntington's Disease | TERMINATED | NCT05655520 |
| Brexanolone | DRUG | Phase PHASE2 | Tinnitus | COMPLETED | NCT05645432 |
| Point Subtraction Aggression Paradigm (PSAP) Task | BEHAVIORAL | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
| BIS-001ER | DRUG | Phase PHASE1 | Focal Impaired Awareness Seizures | ACTIVE_NOT_RECRUITING | NCT03474770 |
| XR-TPM (Trokendi XR) | DRUG | Phase PHASE2 | Migraine | WITHDRAWN | NCT03280342 |
| IR-TPM (Topamax) | DRUG | Phase PHASE2 | Migraine | WITHDRAWN | NCT03280342 |
| 600mg SPN-812 | DRUG | Phase PHASE3 | ADHD | COMPLETED | NCT03247556 |
| BIS-001 ER | DRUG | Phase PHASE1 | Epilepsy, Complex Partial | COMPLETED | NCT03156439 |
| SAGE-547 90 μg/kg/h | DRUG | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942017 |
| SAGE-547 60 μg/kg/h | DRUG | Phase PHASE3 | Postpartum Depression | COMPLETED | NCT02942004 |
| SPN-812 | DRUG | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | COMPLETED | NCT06185985 |
| 400mg SPN-812 | DRUG | Phase PHASE3 | ADHD | COMPLETED | NCT03247556 |
| 300mg SPN-812 | DRUG | Phase PHASE2 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT02633527 |
| 200mg SPN-812 | DRUG | Phase PHASE3 | ADHD | COMPLETED | NCT03247543 |
| 100mg SPN-812 | DRUG | Phase PHASE4 | Attention-Deficit/Hyperactivity Disorder | RECRUITING | NCT04781140 |
| SPN-810 (36 mg) | DRUG | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618434 |
| SPN-810 (18 mg) | DRUG | Phase PHASE3 | Attention Deficit Hyperactivity Disorder (ADHD) | COMPLETED | NCT02618434 |
| Physical Therapy | BEHAVIORAL | Phase PHASE4 | Parkinson's Disease | TERMINATED | NCT02549573 |
| apomorphine infusion | DRUG | Phase PHASE3 | Idiopathic Parkinson's Disease | ACTIVE_NOT_RECRUITING | NCT02339064 |
| SAGE-547 | DRUG | Phase PHASE2 | Severe Postpartum Depression | COMPLETED | NCT02614547 |
| SPN-810M | DRUG | Phase PHASE1 | Impulsive Aggression Comorbid With ADHD | COMPLETED | NCT02023606 |
| PLACEBO | OTHER | Phase PHASE3 | Sialorrhea | COMPLETED | NCT01994109 |
| MYOBLOC | DRUG | Phase PHASE3 | Sialorrhea | COMPLETED | NCT02610868 |
| Trimethobenzamide | DRUG | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| L-dopa | DRUG | Phase PHASE4 | Parkinson's Disease | COMPLETED | NCT01770145 |
| APOKYN | DRUG | Phase PHASE4 | Parkinson's Disease | TERMINATED | NCT02549573 |
| Molindone | DRUG | Phase PHASE2 | Impulsive Aggression Comorbid With ADHD in Children | COMPLETED | NCT01416064 |
| TPM XR | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT01284530 |
| Topiramate ER | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT01114854 |
| Topiramate IR | DRUG | Phase PHASE1 | Epilepsy | COMPLETED | NCT01114854 |
| IR Viloxazine | DRUG | Phase PHASE1 | Attention-Deficit/Hyperactivity Disorder (ADHD) | COMPLETED | NCT01107496 |
| Oxcarbazepine Extended Release | DRUG | Preclinical | Epilepsy | APPROVED_FOR_MARKETING | NCT00918424 |
| SPN-804O | DRUG | Phase PHASE1 | Epilepsies, Partial | COMPLETED | NCT00918047 |
| Oxcarbazepine XR | DRUG | Phase PHASE3 | Partial Epilepsy | COMPLETED | NCT00908349 |
| 1200mg SPN-804 | DRUG | Phase PHASE3 | Epilepsies, Partial | COMPLETED | NCT00772603 |
| 2400mg SPN-804 | DRUG | Phase PHASE3 | Epilepsies, Partial | COMPLETED | NCT00772603 |
| Placebo | DRUG | Phase PHASE2 | Major Depressive Disorder (MDD) | RECRUITING | NCT07226661 |
| SPN-810 | DRUG | Phase PHASE2 | Attention Deficit Hyperactivity Disorder (ADHD) | TERMINATED | NCT03638466 |
Total products: 210